Parkinson’s in the news: October

Global update

Author: Simge Eva DoganPublished: 29 October 2020

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

Aerial view of various coffee

We round up October’s top news stories about Parkinson’s disease from around the world – from a potential new treatment for visual hallucinations to a study on how coffee could lower the risk of developing the condition for some people


Drinking coffee may protect some people against Parkinson’s disease

Drinking coffee has previously been associated with lowering the risk of developing Parkinson’s disease. In a recent study, researchers in the US examined whether coffee can protect people with a mutation in the LRRK2 gene – which can increase the risk of developing the condition.

The team compared groups of people with and without Parkinson’s disease. In both groups, people with and without the mutation in the LRRK2 gene were present. The results showed that the differences in blood caffeine levels between people with and without Parkinson’s were higher among those with the gene mutation.

Dr Grace Crotty, lead researcher of the study, said: “These results are promising and encourage future research exploring caffeine and caffeine-related therapies to lessen the chance that people with this gene develop Parkinson’s.

“It’s also possible that caffeine levels in the blood could be used as a biomarker to help identify which people with this gene will develop the disease, assuming caffeine levels remain relatively stable.”

Could a cancer anti-sickness drug treat hallucinations in Parkinson’s disease?

There are currently 145,000 people living with Parkinson’s disease in the UK ­– around 75% of whom will experience visual hallucinations at some point. A new research study will assess whether ondansetron, an anti-sickness medication commonly used for people having cancer treatment, can be used to treat visual hallucinations in people living with Parkinson’s disease.

As part of the study – funded by charity Parkinson’s UK in partnership with University College London, UK – 216 people with the condition who experience hallucinations will test the drug against a placebo. The trial comes after a recent Parkinson’s UK survey saw one in 10 people report increased hallucinations during lockdown.

Dr Arthur Roach, director of research at Parkinson’s UK, said: “It’s vital we find better treatments for people with Parkinson’s who have seen their hallucinations worsen at home and ondansetron offers much hope for them and their families.

“If successful, positive results from the trial could see this drug, which is already used in the NHS (National Health Service), quickly repurposed to become an available treatment in Parkinson’s.”

Diagnosing Parkinson’s disease with skin samples could lead to earlier detection

Researchers in the US have found that a skin test could accurately identify Parkinson’s disease – and help diagnose the condition earlier.

The researchers carried out a study of 50 skin samples ­– half of which came from people with Parkinson’s disease and half from people without a neurological condition. Using the skin test, the team correctly diagnosed 24 of the 25 people with Parkinson’s.

Dr Thomas Beach, co-investigator of the study, said: “The clinical diagnostic accuracy for early-stage Parkinson’s disease has been quite poor, only around 50-70%. And since clinical trials really need to be done at an early stage to avoid further brain damage, they have been critically hampered because they have been including large percentages of people who may not actually have the disease.

“Improving clinical diagnostic accuracy is, in my view, the very first thing we need to do in order to find new useful treatments for Parkinson’s disease.”

Risk of recurrent falls evident in elderly with gait, cognitive problems

People with Parkinson’s disease experience a change in their ability to walk – known as parkinsonian gait – as the condition progresses. A new investigation by researchers in France aimed to identify factors that can increase risk of falling in people with parkinsonian gait.

They assessed 79 elderly people, who could walk at least 10 metres without assistance. Half of the participants had Parkinson’s and half had parkinsonian syndrome, vascular parkinsonism or Lewy body dementia. The researchers evaluated patients’ motor and non-motor symptoms, conducting interviews to identify falls, traumatic falls, changes in walking abilities and cognitive skills, hospitalisation or death.

In the first year of assessment, 536 falls were recorded in total. A history of falls, hallucinations and cognitive problems were all found to be factors that could predict the risk of falling in people with parkinsonian gait – and could “provide a tracking tool for patient management”, the researchers concluded.

Gut bacteria may cause constipation associated with levodopa in Parkinson’s patients

Scientists in the Netherlands have found that a species of bacteria in the small intestine – called clostridium sporogenes – can convert the Parkinson’s disease medication levodopa into a chemical that lowers gastrointestinal mobility. This process could worsen constipation, a common symptom in people living with Parkinson’s.

After running tests on the bacteria, small intestines from mice, and stool samples from people with and without Parkinson’s, the scientists found that this process could explain why gut transit is slower in those with the condition.

They concluded: “Overall, this study underpins the importance of the metabolic pathways of the gut microbiome involved in drug metabolism not only to preserve drug effectiveness, but also to avoid potential side effects of bacterial breakdown products of the unabsorbed residue of medication.”


Read more:

Parkinson’s in the news: September

Parkinson’s in the news: August

Go Back

Share this story

Comments


Related articles


forked wooden pedestrian walkway

sponsored article

PD in Practice

Could your subconscious mind affect your Parkinson’s treatment outcomes?

Drivers for decisions – new insights may help optimise treatment

READ MORE

Resources & Tools

VIDEO: Parkinson’s stem cell treatments explained in just 90 seconds

Watch Professor Roger Barker explain new stem cell treatments

READ MORE
female professional caregiver taking care of elderly woman at home

Special reports

Ask the expert: How close are we to a cure for Parkinson’s disease?

We talk to the deputy CEO of the Michael J Fox Foundation

READ MORE